{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:25:40Z","timestamp":1787109940600,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003451","name":"University of the Basque Country","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015866","name":"Government of the Basque Country Department of Education Linguistic Policy and Culture","doi-asserted-by":"publisher","award":["IT1751\\u201322"],"award-info":[{"award-number":["IT1751\\u201322"]}],"id":[{"id":"10.13039\/100015866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022856","name":"Fondation Bergoni\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007320","name":"Albert Einstein Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032142","name":"Euskampus Fundazioa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009468","name":"Conseil R\u00e9gional Aquitaine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006251","name":"Universit\u00e9 de Bordeaux","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006251","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105429","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:39:15Z","timestamp":1780936755000},"page":"105429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PCSK9 in the liver metastatic niche: From cholesterol homeostasis to tumor microenvironment reprogramming"],"prefix":"10.1016","volume":"225","author":[{"given":"Ander","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Garc\u00eda","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iratxe","family":"Ba\u00f1ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel-Majid","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2392-2537","authenticated-orcid":false,"given":"Iker","family":"Badiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105429_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cells11244132","article-title":"PCSK9 in liver cancers at the crossroads between lipid metabolism and immunity","volume":"11","author":"Alannan","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105429_bib2","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-23-3461","article-title":"Spatial transcriptome mapping of the desmoplastic growth pattern of colorectal liver metastases by in situ sequencing reveals a biologically relevant zonation of the desmoplastic rim","volume":"30","author":"Andersson","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105429_bib3","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105429_bib4","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v18.i1.113896","article-title":"Transforming growth factor beta reduces proprotein convertase subtilisin\/kexin type 9 in the supernatant of hepatic stellate cells","volume":"18","author":"Bundschuh","year":"2026","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105429_bib5","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s11596-025-00064-w","article-title":"Global and country-level analysis of liver cancer: disease burden and recent trends","volume":"45","author":"Chen","year":"2025","journal-title":"Curr. Med. Sci."},{"key":"10.1016\/j.critrevonc.2026.105429_bib6","article-title":"Exosome-derived tRNA fragments tRF-GluCTC-0005 promotes pancreatic cancer liver metastasis by activating hepatic stellate cells","volume":"15","author":"Chen","year":"2024","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105429_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26167917","article-title":"Gold nanoparticles as targeted drug delivery systems for liver cancer: a systematic review of tumor targeting efficiency and toxicity profiles","volume":"26","author":"Cosma","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105429_bib8","article-title":"FGF19-activated hepatic stellate cells Release ANGPTL4 that promotes colorectal cancer liver metastasis","volume":"12","author":"Fan","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.critrevonc.2026.105429_bib9","doi-asserted-by":"crossref","first-page":"8811","DOI":"10.1021\/acsnano.3c11775","article-title":"Multiple immunomodulatory strategies based on targeted regulation of proprotein convertase subtilisin\/kexin type 9 and immune homeostasis against hepatocellular carcinoma","volume":"18","author":"Fang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.critrevonc.2026.105429_bib10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2025.10.017","article-title":"The role of liver sinusoidal endothelial cells in liver diseases: key players in health and pathology","volume":"84","author":"Felli","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105429_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105429_bib12","article-title":"High levels of serum cholesterol increase the risk of developing vessel co-opting tumors in colorectal cancer liver metastases","author":"Gantz","year":"2025","journal-title":"FEBS J."},{"key":"10.1016\/j.critrevonc.2026.105429_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2026.04.020","article-title":"PCSK9 promotes prostate cancer via facilitating intratumoral cholesterol accumulation and enhancing immunosuppressive tumor microenvironment","author":"Gu","year":"2026","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.critrevonc.2026.105429_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Hosseini-Kharat","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.critrevonc.2026.105429_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12032-024-02435-0","article-title":"The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy","volume":"41","author":"Hsu","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105429_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-024-02435-0","article-title":"The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy","volume":"41","author":"Hsu","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105429_bib17","doi-asserted-by":"crossref","first-page":"12586","DOI":"10.1136\/jitc-2025-012586","article-title":"Blocking PCSK9 suppresses hepatocellular carcinoma immune escape by decreasing FLI1-mediated SPP1 and PD-L1 expression","volume":"13","author":"Hu","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105429_bib18","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1080\/08820139.2022.2027439","article-title":"PCSK9 suppresses M2-Like tumor-associated macrophage polarization by regulating the secretion of OX40L from hepatocellular carcinoma cells","volume":"51","author":"Hu","year":"2022","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.critrevonc.2026.105429_bib19","article-title":"Association of PCSK9 inhibitors versus statins with cancer incidence: a target trial emulation","volume":"12","author":"Huang","year":"2026","journal-title":"Cardiooncology"},{"key":"10.1016\/j.critrevonc.2026.105429_bib20","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s13346-024-01780-x","article-title":"Navigating liver cancer: precision targeting for enhanced treatment outcomes","volume":"15","author":"Jain","year":"2025","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.critrevonc.2026.105429_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155532","article-title":"Arenobufagin modulation of PCSK9-mediated cholesterol metabolism induces tumor-associated macrophages polarisation to inhibit hepatocellular carcinoma progression","volume":"128","author":"Li","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.critrevonc.2026.105429_bib22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40265-025-02167-z","article-title":"Tafolecimab, a third monoclonal antibody for pcsk9 as the novel lipid-lowering drug around the world: a narrative review","volume":"85","author":"Liu","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2026.105429_bib23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105429_bib24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ijc.31343","article-title":"Targeting liver sinusoidal endothelial cells with miR-20a-loaded nanoparticles reduces murine colon cancer metastasis to the liver","volume":"143","author":"Marquez","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105429_bib25","first-page":"16","article-title":"Inhibition of PCSK9 attenuates liver endothelial cell 2 activation induced by colorectal cancer stem cells during liver metastasis 4","author":"Martin","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105429_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241307814","article-title":"Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy","volume":"16","author":"Mellor","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105429_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02480-x","article-title":"Reversal of tumour immune evasion via enhanced MHC-Class-I antigen presentation by a dual-functional RNA regulated system","volume":"24","author":"Meng","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105429_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7150\/jca.126772","article-title":"Macrophages in colorectal cancer: from normal mucosa to distant metastasis: beyond the M1\/M2 paradigm","volume":"17","author":"Pavlov","year":"2026","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105429_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2025.1661872","article-title":"Nanoparticle technologies for liver targeting and their applications in liver diseases","volume":"13","author":"Peng","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105429_bib30","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41586-025-09017-8","article-title":"PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer","volume":"643","author":"Rademaker","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105429_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.critrevonc.2026.105429_bib32","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated ldl cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105429_bib33","doi-asserted-by":"crossref","DOI":"10.2174\/011573403X357542250526072430","article-title":"Alirocumab versus evolocumab on cardiovascular outcomes: a systematic review and meta-analysis","volume":"22","author":"Saad Cleto","year":"2026","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105429_bib34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/endrev\/bnab035","article-title":"The multifaceted biology of PCSK9","volume":"43","author":"Seidah","year":"2022","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.critrevonc.2026.105429_bib35","doi-asserted-by":"crossref","first-page":"37112","DOI":"10.1038\/s41598-025-21064-9","article-title":"A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma","volume":"15","author":"Singh","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105429_bib36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-024-07752-y","article-title":"Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy","volume":"632","author":"Sultan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105429_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1134063","article-title":"Identification and validation of PCSK9 as a prognostic and immune-related influencing factor in tumorigenesis: a pan-cancer analysis","volume":"13","author":"Sun","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105429_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66630-x","article-title":"Silencing PCSK9 reshapes the spatiotemporal activation of STINGfor safe and effective cancer immunotherapy","volume":"16","author":"Sun","year":"2025","journal-title":"Nat. Comm."},{"key":"10.1016\/j.critrevonc.2026.105429_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-021-00261-6","article-title":"Liver metastases","volume":"7","author":"Tsilimigras","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.critrevonc.2026.105429_bib40","series-title":"Architectural and functional aspects of the liver with implications for cancer metastasis","author":"Vidal-Vanaclocha","year":"2011"},{"key":"10.1016\/j.critrevonc.2026.105429_bib41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12307-008-0011-6","article-title":"The prometastatic microenvironment of the liver","volume":"1","author":"Vidal-Vanaclocha","year":"2008","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.critrevonc.2026.105429_bib42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s12885-024-12148-2","article-title":"Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105429_bib43","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02477-0","article-title":"PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K\/AKT signaling in tumor cells and phenotypic polarization of macrophages","volume":"41","author":"Wang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105429_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218255","article-title":"Dysregulation of PCSK9 via m6A-dependent epitranscriptomic programs fosters hepatocellular carcinoma progression","volume":"640","author":"Wang","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105429_bib45","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.7150\/ijbs.93668","article-title":"Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy","volume":"20","author":"Xu","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105429_bib46","article-title":"Alirocumab therapy effectively suppresses colorectal cancer cell Growth and invasion in nude mouse liver-PCSK9 is a key driver of PI3K\/Akt\/p-Bad-mediated cell proliferation and antiapoptotic signaling","author":"Yeh","year":"2025","journal-title":"Int. J. Surg."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:38:48Z","timestamp":1787107128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"alternative-id":["S1040842826003161"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105429","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCSK9 in the liver metastatic niche: From cholesterol homeostasis to tumor microenvironment reprogramming","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105429"}}